Altimmune will present 24-week efficacy and safety data from its pemvidutide trial at The Liver Meeting® 2025.
Quiver AI Summary
Altimmune, Inc. announced that it will present 24-week efficacy and safety data from its Phase 2b IMPACT trial of the investigational drug pemvidutide for metabolic dysfunction-associated steatohepatitis (MASH) at The Liver Meeting® 2025 from November 7-11 in Washington, D.C. The company will feature an oral presentation and a poster highlighting AI-based analyses of liver fibrosis reduction. The oral presentation will be given by Dr. Mazen Noureddin, while Dr. Julio Gutierrez will present the poster on November 8. The trial involved 212 participants and evaluated the drug's effectiveness in improving MASH and liver fibrosis. Altimmune expects to release 48-week data later in Q4 2025 and is developing pemvidutide for MASH, Alcohol Use Disorder, and Alcohol-Associated Liver Disease, among other conditions.
Potential Positives
- Presentation of significant 24-week data from the Phase 2b IMPACT trial at a prominent conference (The Liver Meeting® 2025) highlights the company's ongoing efforts in addressing MASH, potentially increasing visibility and credibility in the biopharmaceutical industry.
- The inclusion of AI-based analyses in the research suggests innovative methodologies in clinical evaluations, reflecting Altimmune's commitment to incorporating advanced technologies in their drug development processes.
- The anticipated announcement of 48-week data in Q4 2025 indicates ongoing progress and continued engagement in clinical trials, which may bolster investor confidence and interest in the company's future prospects.
Potential Negatives
- Presentation of data from the Phase 2b IMPACT trial may indicate that the company is still in the early stages of clinical development, raising concerns about the timeline to market for pemvidutide.
- The need for further presentation of 48-week data suggests potential uncertainty regarding the long-term efficacy and safety profile of pemvidutide.
- Focus on AI-based analyses may distract from direct clinical outcomes, potentially leading to skepticism about the validity and relevance of the results presented.
FAQ
What is the main focus of Altimmune's presentations at The Liver Meeting® 2025?
Altimmune will present 24-week efficacy and safety data from its Phase 2b IMPACT trial of pemvidutide for MASH.
Who will present the oral and poster sessions at the conference?
The oral session will be presented by Dr. Mazen Noureddin and the poster session by Dr. Julio Gutierrez.
When will Altimmune announce the final readout from the IMPACT trial?
The final readout of the IMPACT trial is expected to be announced in Q4 2025.
What is pemvidutide and its intended use?
Pemvidutide is a peptide-based dual receptor agonist for treating Metabolic Dysfunction-Associated Steatohepatitis (MASH) and related conditions.
Where can I find more information about the presentations and data?
A copy of the presentation and poster will be available on the Events section of Altimmune's website.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$ALT Hedge Fund Activity
We have seen 105 institutional investors add shares of $ALT stock to their portfolio, and 74 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- AMERIPRISE FINANCIAL INC removed 1,330,057 shares (-92.1%) from their portfolio in Q2 2025, for an estimated $5,147,320
- MARSHALL WACE, LLP removed 1,146,238 shares (-98.1%) from their portfolio in Q2 2025, for an estimated $4,435,941
- BELLEVUE GROUP AG removed 1,056,793 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $4,089,788
- MILLENNIUM MANAGEMENT LLC removed 1,033,005 shares (-93.0%) from their portfolio in Q2 2025, for an estimated $3,997,729
- SCHRODER INVESTMENT MANAGEMENT GROUP removed 961,884 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $3,722,491
- CAPTION MANAGEMENT, LLC added 941,917 shares (+2423.6%) to their portfolio in Q2 2025, for an estimated $3,645,218
- VANGUARD GROUP INC added 759,662 shares (+17.2%) to their portfolio in Q2 2025, for an estimated $2,939,891
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$ALT Analyst Ratings
Wall Street analysts have issued reports on $ALT in the last several months. We have seen 2 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- HC Wainwright & Co. issued a "Buy" rating on 10/10/2025
- UBS issued a "Buy" rating on 08/13/2025
To track analyst ratings and price targets for $ALT, check out Quiver Quantitative's $ALT forecast page.
$ALT Price Targets
Multiple analysts have issued price targets for $ALT recently. We have seen 5 analysts offer price targets for $ALT in the last 6 months, with a median target of $15.0.
Here are some recent targets:
- Patrick R. Trucchio from HC Wainwright & Co. set a target price of $12.0 on 10/10/2025
- Mayank Mamtani from B. Riley Securities set a target price of $18.0 on 08/13/2025
- Eliana Merle from UBS set a target price of $24.0 on 08/13/2025
- Jonathan Wolleben from JMP Securities set a target price of $15.0 on 07/10/2025
Full Release
Oral presentation to highlight 24-week efficacy and safety data
Poster to feature results of AI-based analyses of liver fibrosis reduction
GAITHERSBURG, Md., Oct. 20, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing novel peptide-based therapeutics for liver and cardiometabolic diseases, today announced that 24-week data from its Phase 2b IMPACT trial of pemvidutide in metabolic dysfunction-associated steatohepatitis (MASH) will be presented in late-breaking oral and poster presentations at The Liver Meeting ® 2025, hosted by the American Association for the Study of Liver Diseases (AASLD) in Washington, D.C., November 7–11, 2025.
Details of the presentations are as follows:
Poster Presentation Details
- Abstract Title : Reduction of Liver Fibrosis by AI-Based Digital Pathology Analysis: Results from the Pemvidutide Phase 2 IMPACT Trial
- Session : Saturday Late-Breaking Posters (publication number 5025)
- Date/Time : The presenter will present/take questions during Poster Session II on Saturday, November 8, 2025 from 1:00 – 2:00 p.m. ET . The poster will be on display throughout The Liver Meeting ®
- Presenter : Dr. Julio Gutierrez, Transplant Hepatologist at the Scripps Organ and Cell Transplant Program and Senior Medical Director at Altimmune
Oral Presentation Details
- Abstract Title : A Phase 2, Multicenter, Randomized, Placebo-Controlled Trial of Pemvidutide in Metabolic Dysfunction-Associated Steatohepatitis
- Session : Late-Breaking Abstracts Parallel Session 3 (publication number 5001)
- Date/Time : Tuesday, November 11, 2025 at 11:45 a.m. ET
- Presenter : Dr. Mazen Noureddin, Professor of Medicine at the Houston Methodist Hospital and Co-Chairman of the Board for Summit and Pinnacle Clinical Research
The AASLD late-breaking presentations will focus on the recent IMPACT Phase 2b readout of the 24-week data . In addition, Altimmune expects to announce 48-week data in Q4 2025.
A copy of the presentation and poster will be accessible on the Events section of the Altimmune website.
About the Phase 2b IMPACT Study
The IMPACT ( NCT05989711 ) trial enrolled 212 participants with biopsy-confirmed MASH and fibrosis stages F2/F3 with and without diabetes randomized 1:2:2 to receive weekly subcutaneous pemvidutide doses at either 1.2 mg, 1.8 mg, or placebo for 24 weeks. Key efficacy endpoints were MASH resolution without worsening of fibrosis, or fibrosis improvement without worsening of MASH at 24 weeks. Secondary endpoints included weight loss and non-invasive tests of fibrosis. Participants will receive a total of 48 weeks of treatment, and a final readout is anticipated in the fourth quarter of 2025.
About Pemvidutide
Pemvidutide is a novel, investigational, peptide-based 1:1 GLP-1/glucagon dual receptor agonist in development for the treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH), Alcohol Use Disorder (AUD), and Alcohol-Associated Liver Disease (ALD). The combined activation of GLP-1 and glucagon receptors results in appetite suppression, weight loss, and direct effects on the liver, including reductions in liver fat, inflammation and fibrosis. The FDA granted Fast Track designations to pemvidutide for the treatment of MASH and AUD, both areas of significant unmet medical need. The 48-week readout from the ongoing IMPACT Phase 2b MASH trial is expected in Q4 2025. Phase 2 trials in AUD (RECLAIM) and ALD (RESTORE) were initiated in May 2025 and July 2025, respectively and are currently ongoing.
About Altimmune
Altimmune is a late clinical-stage biopharmaceutical company focused on developing novel peptide-based therapeutics for liver and cardiometabolic diseases. The Company’s lead product candidate is pemvidutide, a GLP-1/glucagon dual receptor agonist for the treatment of MASH, Alcohol Use Disorder (AUD), Alcohol-associated Liver Disease (ALD) and obesity. For more information, please visit www.altimmune.com .
Follow @Altimmune, Inc. on
LinkedIn
Follow @AltimmuneInc on
X
Investor Contact:
Lee Roth
Burns McClellan
Phone: 646-382-3403
[email protected]
Media Contact:
Elliot Fox
Real Chemistry
[email protected]
This press release was published by a CLEAR® Verified individual.
